Tekmira Conference Call and Webcast Advisory Corporate Update and First Quarter Financial Results
April 22 2015 - 7:00PM
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), a
biopharmaceutical company dedicated to discovering, developing and
commercializing a cure for patients suffering from chronic
hepatitis B infection (HBV), announced that it will hold a
conference call and webcast on Wednesday, May 6, 2015 at 1:30 p.m.
Pacific Time (4:30 p.m. Eastern Time) to provide a corporate update
and first quarter financial results.
Conference Call and Webcast Information
A live webcast of the call can be accessed through the Investor
section of Tekmira's website at www.tekmira.com. Alternatively, to
access the conference call, please dial 914-495-8556 or
1-866-393-1607.
An archived webcast will be available on the Tekmira website
approximately two hours after the event. A replay of the conference
call can be accessed by calling 404-537-3406 or 1-855-859-2056 and
referencing conference ID 20892540.
About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical
company dedicated to discovering, developing and commercializing a
cure for patients suffering from chronic hepatitis B infection
(HBV). Our strategy is to target the three pillars necessary to
develop a curative regimen for HBV, including suppressing HBV
replication within liver cells, stimulating and reactivating the
body's immune system so that it can mount an effective defense
against the virus and, most importantly, eliminating the reservoir
of viral genomic material known as covalently closed circular DNA,
or cccDNA, that is the source of HBV persistence. Our portfolio of
assets includes eight drug candidates for use in combination to
develop a cure for HBV, and includes our product TKM-HBV currently
in Phase 1 clinical studies.
We also have a pipeline of non-HBV assets in oncology,
anti-viral and metabolic therapeutics that leverage our expertise
in RNA interference (RNAi) therapeutics and leading Lipid
Nanoparticle (LNP) technology. RNAi and LNP technology have the
potential to generate new therapeutics that take advantage of the
body's own natural processes to silence disease causing genes, or
more specifically, to eliminate specific gene-products, from the
cell. We intend to maximize the value of our non-HBV assets in the
clinic, namely: TKM-PLK1 for advanced gastrointestinal
neuroendocrine tumors, adrenocortical carcinoma
and hepatocellular carcinoma; and TKM-Ebola, and
TKM-Ebola-Guinea for ebola virus disease; as well as our
preclinical programs in metabolic disorders and filoviruses.
Tekmira is headquartered in Vancouver, BC, Canada with offices
in Doylestown, PA, USA. For more information, visit
www.tekmira.com.
CONTACT: Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email: acutler@tekmira.com
Julie P. Rezler
Director, Investor Relations
& Corporate Communications
Phone: 604-419-3200
Email: jrezler@tekmira.com
Media
Please direct all media inquiries to: media@tekmira.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024